Sigma-Tau Pharmaceuticals Launches CYSTARAN&#0153 for the Treatment of Corneal Cystine Crystal Accumulation in Patients With Cystinosis

Published: May 01, 2013

Staying up-to-date has never been simpler. Sign up for free job search tips!

GAITHERSBURG, Md., May 1, 2013 (GLOBE NEWSWIRE) -- Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau), a part of the Sigma-Tau Group Rare Disease Franchise, announced today the availability of CYSTARANâ„¢ (cysteamine ophthalmic solution) 0.44%, the first and only FDA-approved therapy for the treatment of corneal cystine crystal accumulation in patients with cystinosis. Sigma-Tau developed CYSTARAN in partnership with the National Institutes of Health (NIH) and in cooperation with the Cystinosis Foundation, the Cystinosis Research Foundation, and the Cystinosis Research Network. The U.S. Food and Drug Administration (FDA) approved CYSTARAN in October 2012, and the product has also been granted Orphan Drug status.

Help employers find you! Check out all the jobs and post your resume.

Back to news